Nault Jean Charles, Zucman Rossi Jessica
Inserm UMR-674, Génomique Fonctionnelle des Tumeurs Solides, IUH, 75010 Paris, France ; Labex Immuno-Oncology, Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, 75005 Paris, France.
Int J Hepatol. 2013;2013:315947. doi: 10.1155/2013/315947. Epub 2013 Jan 15.
Hepatocellular adenomas (HCAs) are benign tumors developed in normal liver most frequently in women before menopause. HCAs lead to diagnostic pitfalls and several difficulties to assess the risk of malignant transformation in these young patients. Recent advances in basic knowledge have revealed a molecular classification related to risk factors, pathological features, and risk of transformation in hepatocellular carcinoma. Three major molecular pathways have been identified altered in specific HCA subgroups that are defined by either (1) inactivation of hepatocyte nuclear factor 1A (HNF1A) transcription factor, (2) activation of the WNT/β-catenin by CTNNB1 mutations, or (3) activation of the IL6/STAT3 pathway by somatic mutation of IL6ST, GNAS, or STAT3. Here, we will review the different molecular classes of HCA.
肝细胞腺瘤（HCAs）是在正常肝脏中发生的良性肿瘤，最常见于绝经前女性。HCAs会导致诊断陷阱，并且在评估这些年轻患者的恶性转化风险时存在诸多困难。基础知识的最新进展揭示了与肝细胞癌的危险因素、病理特征及转化风险相关的分子分类。在特定的HCA亚组中已确定有三种主要分子途径发生改变，这些亚组由以下情况定义：（1）肝细胞核因子1A（HNF1A）转录因子失活；（2）CTNNB1突变激活WNT/β-连环蛋白；或（3）IL6ST、GNAS或STAT3的体细胞突变激活IL6/STAT3途径。在此，我们将综述HCA的不同分子类别。
